Tag: Sanofi
Sanofi: why this discount?
By Claude Leguilloux Published on 04/17/2024 at 5:04 p.m. Photo credit © Sanofi (Boursier.com) — Sanofi camped…
Sanofi: positive results against multiple sclerosis – 04/17/2024 at 09:54
(AOF) – Sanofi announces that frexalimab, its experimental antibody against multiple sclerosis (MS), achieved a sustained reduction in disease activity and displayed favorable tolerability after one year of treatment in…
Sanofi: progress of a hematology trial – 04/15/2024 at 1:25 p.m.
(CercleFinance.com) – Innate Pharma announces that the first patient has been treated in the phase 2 dose expansion of the study led by Sanofi, evaluating SAR443579 / IPH6101 as monotherapy…
Sanofi: The pharmaceutical group Sanofi enters into an agreement to put an end to complaints about Zantac
(BFM Bourse) – The company announced an agreement in principle with the plaintiffs’ lawyers in this case which has weighted its stock price in 2022. But this agreement excludes the…
Sanofi settles 4,000 Zantac disputes in US state courts – 04/03/2024 at 11:30 p.m.
((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto)) Sanofi SASY.PA has reached a tentative agreement to settle 4,000 lawsuits linking abandoned heartburn drug Zantac to cancer, the company said Wednesday.…
Sanofi settles 4,000 Zantac disputes in US state courts – 04/04/2024 at 01:03
((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto)) (Added comment from plaintiff’s attorney and background in paragraphs 6-18) by Dietrich Knauth Sanofi SASY.PA has reached a tentative agreement to settle…
Sanofi says it has reached an agreement in principle in the context of disputes relating to Zantac – 04/04/2024 at 06:34
Zantac pills for stomach acid Sanofi said Wednesday it had reached an agreement in principle to settle 4,000 disputes relating to Zantac, a treatment for stomach acid accused of being…
Sanofi is developing in partnership a French solution for recycling insulin injector pens
By Alexandra Saintpierre Published on 03/21/2024 at 3:14 p.m. Photo credit © Sanofi (Boursier.com) — On the…
Sanofi: Stifel raises its recommendation
(CercleFinance.com) – Stifel raises its recommendation on Sanofi from ‘hold’ to ‘buy’ with a price target raised from 95 to 109 euros, with an adjustment to the value of the…
Stifel goes to Purchase on Sanofi
(AOF) – Stifel goes from Hold to Buy on Sanofi, with a price target raised from 95 to 109 euros. “We are reasonably optimistic about Sanofi’s ability to post a…
Sanofi: new positive results in atopic dermatitis
(CercleFinance.com) – Sanofi reports positive results from part 2 of the phase IIb STREAM-AD study relating to amlitelimab, which support its potential as the best drug in its class in…
Sanofi tops CAC after results against atopic dermatitis
(AOF) – Sanofi (+1.17% to 88.72 euros) occupies first place in the CAC 40 after having published new phase II results relating to amlitelimab which “confirm its potential as the…